Like so many other drug stocks today, Amgen's (NASDAQ: AMGN )
shares are not obviously cheap. What Amgen does have going for it,
though, is a deep late-stage pipeline that helps offset some of the
clinical risk. If the company's cholesterol drug evolocumab stays on
track and oncology trial results in 2014 are favorable, I could see
these shares outperforming in what is already pricey real estate in the
stock market.
Read the full article here:
Amgen Inc's Deep Pipeline Offsets Some of the Price Risk
No comments:
Post a Comment